NTLA-2002 is $NTLA’s development candidate for the treatment of #hereditaryangioedema, for which we anticipate submitting an IND or equivalent for this year. Learn how we’re levering #CRISPR/Cas9 to potentially eliminate current #HAE treatment burdens: https://t.co/ahexDda4QO https://t.co/M1LhdgehbA